Shrier Wealth Management LLC Makes New Investment in AbbVie Inc. $ABBV

Shrier Wealth Management LLC bought a new position in AbbVie Inc. (NYSE:ABBV) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,011 shares of the company’s stock, valued at approximately $688,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ABBV. Diversified Trust Co boosted its stake in shares of AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after acquiring an additional 10,891 shares in the last quarter. Permanent Capital Management LP purchased a new position in AbbVie in the 3rd quarter valued at approximately $720,000. Railway Pension Investments Ltd raised its holdings in AbbVie by 33.0% during the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after purchasing an additional 211,800 shares during the last quarter. World Investment Advisors raised its holdings in AbbVie by 9.4% during the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after purchasing an additional 9,811 shares during the last quarter. Finally, Charles Schwab Trust Co boosted its position in AbbVie by 93.4% during the third quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock worth $7,434,000 after purchasing an additional 15,502 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several research reports. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. UBS Group decreased their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Piper Sandler increased their price objective on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. William Blair restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Stock Up 2.0%

ABBV stock opened at $217.39 on Wednesday. The stock has a market capitalization of $384.38 billion, a price-to-earnings ratio of 92.11, a price-to-earnings-growth ratio of 0.74 and a beta of 0.34. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The stock’s fifty day simple moving average is $222.00 and its 200-day simple moving average is $224.65.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the firm posted $2.16 earnings per share. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Earnings momentum and guidance: AbbVie posted a quarterly EPS beat and raised FY‑2026 guidance earlier this year, which supports investor confidence in near‑term earnings and cash flow (background company report).
• Positive Sentiment: Analyst support: BMO (via TipRanks coverage) maintained a Buy rating and $258 price target, reinforcing bullish sentiment among institutional investors. AbbVie: Immunology Strength, Strategic Acquisitions, and Patent Headwind Execution Support Buy Rating
• Positive Sentiment: Institutional buying: Beacon Investment Advisory increased its stake in ABBV, signaling continued institutional interest. Beacon Investment Advisory Services Inc. Has $19.86 Million Stock Position in AbbVie Inc. $ABBV
• Positive Sentiment: Aesthetics business activity: Allergan Aesthetics (an AbbVie unit) launched promotional CoolMonth offers and presented safety/efficacy data at AAD — both support the aesthetics revenue story. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 AAD
• Positive Sentiment: Macro tax tailwind: Analysis shows corporate cash taxes fell materially under the new tax law, a factor that can boost free cash flow for large pharma including AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
• Neutral Sentiment: Stock commentary: MarketWatch notes ABBV rose but still slightly underperformed the broader market on the day; useful context for relative performance. AbbVie Inc. stock rises Tuesday, still underperforms market
• Neutral Sentiment: Upcoming event: AbbVie set its Q1 2026 earnings release and conference call for April 29 — an event that could drive volatility and provide fresh guidance. AbbVie to Host First-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Competitive messaging: AbbVie publicly defends Skyrizi’s efficacy edge as J&J launches Icotyde — shows competitive dynamics in immunology/dermatology but not an immediate structural change. As J&J Brings Icotyde to Market, AbbVie Remains Confident in Skyrizi’s Efficacy Edge
• Negative Sentiment: Oncology pressure: Analyst coverage (Zacks) highlights 2026 headwinds for AbbVie’s oncology revenue — Imbruvica pricing pressure may weigh on top‑line growth despite newer drug contributions. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?
• Negative Sentiment: Lawsuit tied to Cerevel deal: A Bloomberg Law item says investors’ suit over the Cerevel deal involving Pfizer/Bain must proceed, which could raise legal risk/uncertainty around the transaction and reputational exposure. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
• Negative Sentiment: Peer M&A strengthens competition: Merck’s large oncology deal (Terns) reinforces competitive pressure in oncology — a potential headwind for AbbVie’s oncology growth narrative. Merck Just Made a Big Bet on a New Cancer Growth Engine

Insider Activity

In related news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.08% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.